FTH on Nasdaq

Faeth Therapeutics, Inc.

We are a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerFTH on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersAustin, Texas1
  • Incorporated inDE2
  • Business address701 Tillery Street #12 #1010, Austin, Tx 787022
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. On February 17, 2026, we completed the acquisition of Faeth Therapeutics, a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. The Acquisition brought Faeth's lead asset, PIKTOR, a proprietary investigational all-oral combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR pathway, into our pipeline. In connection with the Acquisition, we received $200 million in gross proceeds from a private placement financing, or the 2026 Private Placement, from a broad syndicate of investors, including several leading life sciences funds, including B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, Cormorant Asset Manag…3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income45678-$22.3M in 2025+15% since 2020
-$60.0M-$40.0M-$20.0M02020: -$19.5M-$19.5M20202021: -$37.5M-$37.5M2021+93%2022: -$50.2M-$50.2M2022+34%2023: -$37.1M-$37.1M2023−26%2024: -$32.6M-$32.6M2024−12%2025: -$22.3M-$22.3M2025−32%
Net income45678-$21.1M in 2025+5% since 2020
-$60.0M-$40.0M-$20.0M02020: -$20.1M-$20.1M20202021: -$36.8M-$36.8M2021+83%2022: -$48.6M-$48.6M2022+32%2023: -$34.1M-$34.1M2023−30%2024: -$30.2M-$30.2M2024−12%2025: -$21.1M-$21.1M2025−30%

Every line of the income statement as filed: the last 2 fiscal years, latest first.8

Period ending2025-12-312024-12-31
Research and development$11.0M$18.6M
General and administrative$11.3M$13.0M
Long-lived asset impairment$0$951.0K
Total operating expenses$22.3M$32.6M
Loss from operations-$22.3M-$32.6M
Interest income$1.2M$2.5M
Interest expense-$32.0K-$90.0K
Other expense, net-$4.0K-$3.0K
Net loss-$21.1M-$30.2M
Net loss per common share, basic-$16.72-$24.01
Net loss per common share, diluted-$16.72-$24.01
Weighted-average number of shares used in computing net loss per common share, basic1.3M shares1.3M shares
Weighted-average number of shares used in computing net loss per common share, diluted1.3M shares1.3M shares
Net loss attributable to common stockholders-$21.1M-$30.2M
Unrealized gain on marketable securities$14.0K$196.0K
Total other comprehensive income$14.0K$196.0K
Total comprehensive loss-$21.1M-$30.0M

Compare Faeth Therapeutics, Inc. with another company

Leadership

Who has led Faeth Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. John Celebi2021–2025
  2. Anand Kiran Parikh2026–now

President

  1. John Celebi2021–2025
  2. Christopher Gerry2025–2026
  3. Anand Kiran Parikh2026–now

Chief financial officer

  1. Erin Colgan2022–2024
  2. Brian C. Stephenson2026–now

Chief operating officer

  1. Anand Kiran Parikh2026–now
2025
Board members and other officers (21)

Former names

  • Sensei Biotherapeutics, Inc.Nov 12, 2020 to Jun 16, 20262

Timeline

  1. Jun 16, 2026New chief executive Anand Kiran Parikh becomes CEO11
  2. Feb 3, 2021New chief executive John Celebi becomes CEO12

Filings

336 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 74 major events, 166 insider forms, 25 large holders, 1 private raises, 48 other. The latest 20:

  1. Sep 17, 20268-K EDGAR
  2. Sep 15, 20264 EDGAR
  3. Sep 15, 20263 EDGAR
  4. Aug 14, 2026SCHEDULE 13G/A EDGAR
  5. Aug 14, 2026SCHEDULE 13G/A EDGAR
  6. Aug 14, 2026SCHEDULE 13G EDGAR
  7. Aug 14, 2026SCHEDULE 13G/A EDGAR
  8. Aug 11, 2026144 EDGAR
  9. Aug 4, 20268-K EDGAR
  10. Aug 4, 202610-Q EDGAR
  11. Jul 28, 20263 EDGAR
  12. Jul 23, 20264 EDGAR
  13. Jul 23, 20264 EDGAR
  14. Jul 23, 20268-K EDGAR
  15. Jul 1, 20264 EDGAR
  16. Jun 26, 20264 EDGAR
  17. Jun 24, 20264 EDGAR
  18. Jun 24, 20264 EDGAR
  19. Jun 23, 20263 EDGAR
  20. Jun 23, 2026SCHEDULE 13G EDGAR

The 336 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

112 open-market trades by officers, directors and large owners since October 2021: 94 buys and 18 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 1, 2026STEPHENSON BRIAN CChief Financial OfficerBuy5,000$23.50$117.5KForm 4
Jun 30, 2026STEPHENSON BRIAN CChief Financial OfficerBuy7,803$24.25$189.2KForm 4
Jun 29, 2026STEPHENSON BRIAN CChief Financial OfficerBuy831$23.34$19.4KForm 4
Jun 26, 2026STEPHENSON BRIAN CChief Financial OfficerBuy6,250$24.95$155.9KForm 4
Jun 24, 2026STEPHENSON BRIAN CChief Financial OfficerBuy9,391$26.13$245.4KForm 4
Jun 23, 2026STEPHENSON BRIAN CChief Financial OfficerBuy9,230$24.36$224.8KForm 4
Jun 22, 2026Parikh Anand KiranPresident and CEOBuy2,806$19.76$55.4KForm 4
Jun 22, 2026STEPHENSON BRIAN CChief Financial OfficerBuy8,183$22.13$181.1KForm 4
Jun 1, 2026Cambrian BioPharma Inc10% ownerSale25,000$20.02$500.5KForm 4
Jun 1, 2026Peyer James10% ownerSale25,000$20.02$500.5KForm 4
Apr 7, 2026ICS OPPORTUNITIES II LLC10% ownerBuy1,108$33.38$37.0KForm 4
Apr 7, 2026ICS OPPORTUNITIES II LLC10% ownerSale8,151$31.01$252.8KForm 4
Apr 6, 2026ICS OPPORTUNITIES II LLC10% ownerBuy1,104$31.02$34.2KForm 4
Apr 6, 2026ICS OPPORTUNITIES II LLC10% ownerSale1,259$31.05$39.1KForm 4
Apr 2, 2026ICS OPPORTUNITIES II LLC10% ownerBuy2,003$35.01$70.1KForm 4
Apr 2, 2026ICS OPPORTUNITIES II LLC10% ownerSale7,666$32.12$246.2KForm 4
Apr 1, 2026MILLENNIUM MANAGEMENT LLC10% ownerBuy6,175$34.49$213.0KForm 4
Apr 1, 2026MILLENNIUM MANAGEMENT LLC10% ownerSale1,150$31.65$36.4KForm 4
Mar 31, 2026MILLENNIUM MANAGEMENT LLC10% ownerBuy6,005$28.16$169.1KForm 4
Mar 31, 2026MILLENNIUM MANAGEMENT LLC10% ownerSale1,591$25.49$40.6KForm 4

All 112 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Feb 17, 2026Raised $348.9 million in a private offering of equity Form D: 104 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 45. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Montanova Capital, LLC2,020,103$50.5M1.1%+1,985,554
Avoro Capital Advisors LLC1,444,039$36.1M0.3%New
Baker Bros. Advisors LP1,286,411$32.2M0.2%New
Balyasny Asset Management L.P.1,042,198$26.1M0.0%+1,025,993
Ra Capital Management, L.P.722,020$18.1M0.2%New
Vivo Capital, LLC722,020$18.1M1.6%No change
Logos Global Management LP722,020$18.1M0.8%+692,020
Fairmount Funds Management LLC722,020$18.1M1.2%New
Caligan Partners LP629,467$15.7M0.8%+503,465
B Group, Inc.610,169$15.3M8.7%New
Trails Edge Capital Partners, LP515,335$12.9M2.0%+390,335
Franklin Resources Inc494,516$12.4M0.0%+361,010
Octagon Capital Advisors LP361,010$9.0M0.8%New
ADAR1 Capital Management, LLC361,010$9.0M0.4%New
Cormorant Asset Management, LP1,028,242$7.7M0.4%+722,020
Marshall Wace, Llp206,508$5.2M0.0%+140,778
Boxer Capital Management, LLC180,505$4.5M0.3%New
Patient Square Capital LP175,050$4.4M0.7%New
Alyeska Investment Group, L.P.144,404$3.6M0.0%New
Affinity Asset Advisors, LLC144,404$3.6M0.2%New
Boothbay Fund Management, LLC133,643$3.3M0.1%+107,519
AWM Investment Company, Inc.111,343$2.8M0.2%New
Richmond Investment Services, LLC79,731$2.0M0.6%New
Ikarian Capital, LLC35,386$884.6K0.1%+29,035
UBS Group AG21,541$538.5K0.0%+17,012

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46